OUR TECHNOLOGY
Working to transform disease diagnosis through comprehensive
multiomic profiling.
Cutting-edge
multiomic profiling
Our approach allows us to discover multiomic biomarkers from a DNA sample using a simple, single, streamlined workflow.
We use advanced bioinformatic workflows and machine learning approaches to analyse distinct multiomic patterns that drive patient specific insights and diagnosis.
OUR TECHNOLOGY
Epigenetic Markers
Our multiomic platform incorporates an innovative approach to epigenetic analysis. At its heart is a groundbreaking chemoenzymatic method that sorts hypomethylated and hypermethylated biomolecules, providing access to epigenetic biomarkers associated with diseases. In the context of cancer, these markers play a crucial role in enabling earlier diagnosis and pinpointing the tumours tissue of origin.
OUR TECHNOLOGY
Genomic Markers
Our multiomic platform allows for seamless integration of gene panels or whole genome sequencing. We leverage this feature to analyse key disease-driving mutations and genomic alterations.
OUR TECHNOLOGY
Fragmentomic Markers
Our advanced bioinformatic algorithms grant access to DNA fragmentomic patterns. These markers encompass the length, distribution, and end characteristics of DNA fragments. This offers valuable insights into disease status as fragmentomic features can serve as biomarkers for early disease diagnosis and the identification of tissue of origin.
Contact Us.
For more information, please feel free to get in touch by completing the enquiry form. We aim to respond to all enquiries within 24 hours.
OUR TECHNOLOGY
Working to transform disease diagnosis through comprehensive
multiomic profiling.
OUR TECHNOLOGY
Cutting-edge multiomic profiling
Our approach allows us to discover multiomic biomarkers from a DNA sample using a simple, single, streamlined workflow.
We use advanced bioinformatic workflows and machine learning approaches to analyse distinct multiomic patterns that drive patient specific insights and diagnosis.
OUR TECHNOLOGY
Epigenetic Markers
Our multiomic platform incorporates an innovative approach to epigenetic analysis. At its heart is a groundbreaking chemoenzymatic method that sorts hypomethylated and hypermethylated biomolecules, providing access to epigenetic biomarkers associated with diseases. In the context of cancer, these markers play a crucial role in enabling earlier diagnosis and pinpointing the tumours tissue of origin.
OUR TECHNOLOGY
Genomic Markers
Our multiomic platform allows for seamless integration of gene panels or whole genome sequencing. We leverage this feature to analyse key disease-driving mutations and genomic alterations.
